NO20053825L - Thienopyridazinoner og deres anvendelse ved modulering av autoimmune sykdommer. - Google Patents
Thienopyridazinoner og deres anvendelse ved modulering av autoimmune sykdommer.Info
- Publication number
- NO20053825L NO20053825L NO20053825A NO20053825A NO20053825L NO 20053825 L NO20053825 L NO 20053825L NO 20053825 A NO20053825 A NO 20053825A NO 20053825 A NO20053825 A NO 20053825A NO 20053825 L NO20053825 L NO 20053825L
- Authority
- NO
- Norway
- Prior art keywords
- thienopyridazinones
- autoimmune diseases
- modulating autoimmune
- modulating
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Vascular Medicine (AREA)
- AIDS & HIV (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
Abstract
Oppfinnelsen angår tienopyridazinonforbindelser med formel (1): hvor: R1, R2, Q er som definert i beskrivelsen, og Ar og Ar2 er valgt fra visse aromatiske ringsystemer som eventuelt kan være substituert som definert i beskrivelsen. Fremgangsmåte for fremstilling av forbindelsene med formel (I), farmasøytiske preparater som inneholder dem og deres anvendelse i terapi, er også beskrevet og krevet.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0300118A SE0300118D0 (sv) | 2003-01-17 | 2003-01-17 | Novel Compounds |
SE0300117A SE0300117D0 (sv) | 2003-01-17 | 2003-01-17 | Novel Compounds |
PCT/SE2004/000053 WO2004065395A1 (en) | 2003-01-17 | 2004-01-15 | Thienopyridazinones and their use in modulation of autoimmune disease |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20053825D0 NO20053825D0 (no) | 2005-08-15 |
NO20053825L true NO20053825L (no) | 2005-10-17 |
Family
ID=32775326
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20053825A NO20053825L (no) | 2003-01-17 | 2005-08-15 | Thienopyridazinoner og deres anvendelse ved modulering av autoimmune sykdommer. |
Country Status (15)
Country | Link |
---|---|
US (2) | US7393854B2 (no) |
EP (1) | EP1587811A1 (no) |
JP (1) | JP2006515880A (no) |
KR (1) | KR20050092761A (no) |
AU (1) | AU2004206011B2 (no) |
BR (1) | BRPI0406782A (no) |
CA (1) | CA2512136A1 (no) |
IL (1) | IL169369A0 (no) |
IS (1) | IS7962A (no) |
MX (1) | MXPA05007495A (no) |
NO (1) | NO20053825L (no) |
NZ (1) | NZ541218A (no) |
PL (1) | PL378221A1 (no) |
RU (1) | RU2332420C2 (no) |
WO (1) | WO2004065395A1 (no) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0117583D0 (en) * | 2001-07-19 | 2001-09-12 | Astrazeneca Ab | Novel compounds |
GB0118479D0 (en) * | 2001-07-28 | 2001-09-19 | Astrazeneca Ab | Novel compounds |
SE0300120D0 (sv) | 2003-01-17 | 2003-01-17 | Astrazeneca Ab | Novel compounds |
SE0300119D0 (sv) * | 2003-01-17 | 2003-01-17 | Astrazeneca Ab | Novel compounds |
EP1587811A1 (en) * | 2003-01-17 | 2005-10-26 | AstraZeneca AB | Thienopyridazinones and their use in modulation of autoimmune disease |
PL3060562T3 (pl) * | 2013-10-21 | 2022-01-10 | Genosco | Podstawione związki pirymidynowe i ich zastosowanie jako inhibitory syk |
UY36586A (es) * | 2015-03-26 | 2016-10-31 | Bayer Pharma AG | Heterociclilmetiltienouracilos y uso de los mismos |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6469014B1 (en) * | 1997-05-28 | 2002-10-22 | Astrazeneca Ab | Thieno[2,3-d] pyrimidinediones, their preparation and use in therapy |
SE9702001D0 (sv) * | 1997-05-28 | 1997-05-28 | Astra Pharma Prod | Novel compounds |
US6984644B2 (en) * | 1997-05-28 | 2006-01-10 | Astrazeneca Ab | Treatment of skin disorders using thieno[2,3-D]pyrimidinediones |
JP2001525413A (ja) | 1997-12-05 | 2001-12-11 | アストラゼネカ ユーケイ リミテッド | 新規化合物 |
US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
US6233320B1 (en) * | 1998-06-22 | 2001-05-15 | Lucent Technologies Inc. | Method and apparatus for recording and playing back a conversation using a digital wireless phone |
ES2211161T3 (es) | 1998-08-28 | 2004-07-01 | Astrazeneca Ab | Tieno(2,3-d)pirimidindionas novedosas, procedimiento para su preparacion y uso de las mismas en terapia. |
EP1280806B1 (en) * | 2000-05-04 | 2004-08-04 | AstraZeneca AB | THIENO 2,3-d]PYRIMIDINEDIONES AND THEIR USE AS PHARMACEUTICALS |
GB0117583D0 (en) * | 2001-07-19 | 2001-09-12 | Astrazeneca Ab | Novel compounds |
GB0118479D0 (en) | 2001-07-28 | 2001-09-19 | Astrazeneca Ab | Novel compounds |
SE0300120D0 (sv) * | 2003-01-17 | 2003-01-17 | Astrazeneca Ab | Novel compounds |
SE0300119D0 (sv) * | 2003-01-17 | 2003-01-17 | Astrazeneca Ab | Novel compounds |
EP1587811A1 (en) * | 2003-01-17 | 2005-10-26 | AstraZeneca AB | Thienopyridazinones and their use in modulation of autoimmune disease |
-
2004
- 2004-01-15 EP EP04702470A patent/EP1587811A1/en not_active Withdrawn
- 2004-01-15 WO PCT/SE2004/000053 patent/WO2004065395A1/en active IP Right Grant
- 2004-01-15 KR KR1020057013127A patent/KR20050092761A/ko not_active Application Discontinuation
- 2004-01-15 BR BR0406782-7A patent/BRPI0406782A/pt not_active IP Right Cessation
- 2004-01-15 PL PL378221A patent/PL378221A1/pl not_active Application Discontinuation
- 2004-01-15 JP JP2006500751A patent/JP2006515880A/ja active Pending
- 2004-01-15 AU AU2004206011A patent/AU2004206011B2/en not_active Ceased
- 2004-01-15 US US10/542,457 patent/US7393854B2/en not_active Expired - Fee Related
- 2004-01-15 CA CA002512136A patent/CA2512136A1/en not_active Abandoned
- 2004-01-15 NZ NZ541218A patent/NZ541218A/en unknown
- 2004-01-15 RU RU2005121492/04A patent/RU2332420C2/ru not_active IP Right Cessation
- 2004-01-15 MX MXPA05007495A patent/MXPA05007495A/es active IP Right Grant
-
2005
- 2005-06-23 IL IL169369A patent/IL169369A0/en unknown
- 2005-07-27 IS IS7962A patent/IS7962A/is unknown
- 2005-08-15 NO NO20053825A patent/NO20053825L/no not_active Application Discontinuation
-
2008
- 2008-05-21 US US12/124,319 patent/US20080221131A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2004206011B2 (en) | 2007-07-12 |
MXPA05007495A (es) | 2005-09-21 |
RU2005121492A (ru) | 2006-02-10 |
IL169369A0 (en) | 2007-07-04 |
KR20050092761A (ko) | 2005-09-22 |
US20060135539A1 (en) | 2006-06-22 |
NO20053825D0 (no) | 2005-08-15 |
NZ541218A (en) | 2008-05-30 |
BRPI0406782A (pt) | 2006-01-17 |
US20080221131A1 (en) | 2008-09-11 |
AU2004206011A1 (en) | 2004-08-05 |
RU2332420C2 (ru) | 2008-08-27 |
US7393854B2 (en) | 2008-07-01 |
CA2512136A1 (en) | 2004-08-05 |
IS7962A (is) | 2005-07-27 |
EP1587811A1 (en) | 2005-10-26 |
JP2006515880A (ja) | 2006-06-08 |
WO2004065395A1 (en) | 2004-08-05 |
PL378221A1 (pl) | 2006-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20053826D0 (no) | Thienylpyrimidinioner og deres anvendelse ved modulering av autoimmune sykdommer. | |
NO20081729L (no) | Nye diazaspiroalkaner og deres anvendelse for behandling av CCR8-medierte sykdommer | |
DE602004021472D1 (en) | Pyrimiidinverbindungen | |
NO20054329L (no) | Adamantanderivater, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger som innbefatter slike | |
NO20061363L (no) | Pyrazolo- og imidazo- pyrimidinderivater | |
NO20056192L (no) | Kapaseinhibitorer og anvendelse derav | |
MY139303A (en) | Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof | |
CA2473070A1 (en) | Proline compounds as ns3-serine protease inhibitors for use in treatment of hepatites c virus infection | |
MXPA03010207A (es) | Nuevas 4-anilinoquinolin-3-carboxamidas. | |
NO20060324L (no) | [1,8]Naftyridin-2-oner og relaterte forbindelser for behandling av Schizofreni | |
NO20070224L (no) | 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav | |
SE0200920D0 (sv) | Novel compounds | |
NO20065456L (no) | Substituerte morfolinforbindelser for behandling av sykdommer i sentralnervesystemet | |
NO20050828L (no) | lndol-3-svovelderivater | |
NO20050525L (no) | Benzimidazol-1-yl-tiofenforbindelser for behandling av cancer | |
MXPA05012025A (es) | Imidazo y tiazolopiridinas como inhibidores de cinasa jak3. | |
NO20054414L (no) | Dihydropteridinoner, metoder for deres fremstilling og bruk av disse som medisiner | |
TW200613243A (en) | Novel compounds | |
TW200738659A (en) | Novel compounds | |
NO20053825L (no) | Thienopyridazinoner og deres anvendelse ved modulering av autoimmune sykdommer. | |
MY135850A (en) | Ring-substituted diphenylazetidinones, process for their preparation, medicaments comprising these compounds and their use | |
NO20076682L (no) | Nye pyridinanaloger | |
SE0302139D0 (sv) | Novel compounds | |
NO20060383L (no) | Substituerte diketopiperaziner og deres anvendelse som oksytocinantagonister | |
NO20062900L (no) | Nye forbindelser |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |